Jonathan Chang's Stock Ratings

Leerink Partners Analyst

Jonathan Chang is an analyst at Leerink Partners. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 05/16/2024

Overall Average Return

-11.5%

Smart Score

43.4%

Overall Average Return Percentile

18th

Number of Ratings

58
Buy NowGet Alert
04/29/2024IMCRBuy Now
Immunocore Hldgs
$56.0132.12% → $74Initiates → OutperformGet Alert
12/08/2023NBTXBuy Now
Nanobiotix
$7.3150.48% → $11Initiates → OutperformGet Alert
08/04/2023NVCRBuy Now
NovoCure
$21.00142.86% → $51Initiates → OutperformGet Alert
01/10/2023KPTIBuy Now
Karyopharm Therapeutics
$1.13342.48%$6 → $5MaintainsMarket PerformGet Alert
12/07/2022REPLBuy Now
Replimune Group
$6.81399.27%$30 → $34MaintainsOutperformGet Alert
11/30/2022FUSNBuy Now
Fusion Pharmaceuticals
$21.54-72.14% → $6Initiates → OutperformGet Alert
11/30/2022PNTBuy Now
POINT Biopharma Global
—— → $14Initiates → OutperformGet Alert
11/15/2022CALABuy Now
Calithera Biosciences
$0.029900%$18 → $2DowngradeOutperform → Market PerformGet Alert
11/15/2022HARPBuy Now
Harpoon Therapeutics
——$100 → $40MaintainsOutperformGet Alert
11/10/2022GMABBuy Now
Genmab
$30.229.2%$31 → $33MaintainsMarket PerformGet Alert
11/08/2022TCRRBuy Now
TCR2 Therapeutics
——$3 → $2MaintainsMarket PerformGet Alert
11/04/2022KPTIBuy Now
Karyopharm Therapeutics
$1.13430.97%$5 → $6MaintainsMarket PerformGet Alert
10/03/2022REPLBuy Now
Replimune Group
$6.81340.53%$37 → $30MaintainsOutperformGet Alert
08/22/2022BCYCBuy Now
Bicycle Therapeutics
$22.36123.61%$48 → $50MaintainsOutperformGet Alert
08/16/2022CALABuy Now
Calithera Biosciences
$0.0289900%$2 → $18MaintainsOutperformGet Alert
08/12/2022VINCBuy Now
Vincerx Pharma
$0.75567.56%$6 → $5MaintainsOutperformGet Alert
08/11/2022GMABBuy Now
Genmab
$30.222.58%$30 → $31MaintainsMarket PerformGet Alert
08/11/2022HARPBuy Now
Harpoon Therapeutics
——$130 → $100MaintainsOutperformGet Alert
08/10/2022RVMDBuy Now
Revolution Medicines
$39.39-23.84%$31 → $30MaintainsOutperformGet Alert
08/09/2022MGNXBuy Now
Macrogenics
$4.78151.05%$15 → $12MaintainsOutperformGet Alert
08/09/2022RUBYBuy Now
Rubius Therapeutics
$0.061654.39%$2 → $1MaintainsMarket PerformGet Alert
08/09/2022MRSNBuy Now
Mersana Therapeutics
$2.57444.81%$13 → $14MaintainsOutperformGet Alert
08/05/2022BCYCBuy Now
Bicycle Therapeutics
$22.36114.67%$69 → $48MaintainsOutperformGet Alert
08/05/2022REPLBuy Now
Replimune Group
$6.81443.32%$48 → $37MaintainsOutperformGet Alert
06/07/2022VINCBuy Now
Vincerx Pharma
$0.75701.07%$19 → $6MaintainsOutperformGet Alert
06/03/2022IMTXBuy Now
Immatics
$11.08134.66%$25 → $26MaintainsOutperformGet Alert
05/20/2022REPLBuy Now
Replimune Group
$6.81604.85%$49 → $48MaintainsOutperformGet Alert
05/13/2022VINCBuy Now
Vincerx Pharma
$0.752436.72%$20 → $19MaintainsOutperformGet Alert
05/12/2022GMABBuy Now
Genmab
$30.22-0.73%$39 → $30MaintainsMarket PerformGet Alert
05/11/2022ZLABBuy Now
Zai Lab
$20.73358.27%$101 → $95MaintainsOutperformGet Alert
05/10/2022ATNXBuy Now
Athenex
——$20 → $60MaintainsMarket PerformGet Alert
05/10/2022RUBYBuy Now
Rubius Therapeutics
$0.065163.16%$2 → $3MaintainsMarket PerformGet Alert
05/09/2022MRSNBuy Now
Mersana Therapeutics
$2.57444.81%$13 → $14MaintainsOutperformGet Alert
05/09/2022ADAPBuy Now
Adaptimmune Therapeutics
$1.24141.94%$2 → $3MaintainsMarket PerformGet Alert
05/06/2022IMGNBuy Now
Immunogen
——$5 → $4MaintainsMarket PerformGet Alert
05/06/2022BCYCBuy Now
Bicycle Therapeutics
$22.36208.59%$70 → $69MaintainsOutperformGet Alert
05/05/2022KPTIBuy Now
Karyopharm Therapeutics
$1.13342.48%$6 → $5MaintainsMarket PerformGet Alert
05/04/2022MGNXBuy Now
Macrogenics
$4.78213.81%$23 → $15MaintainsOutperformGet Alert
04/21/2022ZLABBuy Now
Zai Lab
$20.73387.22%$102 → $101MaintainsOutperformGet Alert
04/11/2022RUBYBuy Now
Rubius Therapeutics
$0.065163.16%$5 → $3MaintainsMarket PerformGet Alert
04/04/2022CALABuy Now
Calithera Biosciences
$0.029900%$60 → $40MaintainsOutperformGet Alert
03/30/2022VINCBuy Now
Vincerx Pharma
$0.752570.23%$24 → $20MaintainsOutperformGet Alert
03/24/2022IMTXBuy Now
Immatics
$11.08125.63%$32 → $25MaintainsOutperformGet Alert
03/23/2022TCRRBuy Now
TCR2 Therapeutics
——$7 → $3MaintainsMarket PerformGet Alert
03/17/2022ATNXBuy Now
Athenex
——$40 → $60MaintainsMarket PerformGet Alert
03/15/2022ADAPBuy Now
Adaptimmune Therapeutics
$1.24141.94%$7 → $3MaintainsMarket PerformGet Alert
03/02/2022ZLABBuy Now
Zai Lab
$20.73392.04%$194 → $102MaintainsOutperformGet Alert
03/02/2022KPTIBuy Now
Karyopharm Therapeutics
$1.13430.97%$8 → $6MaintainsMarket PerformGet Alert
02/25/2022RUBYBuy Now
Rubius Therapeutics
$0.068671.93%$14 → $5MaintainsMarket PerformGet Alert
02/25/2022KURABuy Now
Kura Oncology
$21.8728.03%$41 → $28MaintainsOutperformGet Alert
02/25/2022MGNXBuy Now
Macrogenics
$4.78381.17%$40 → $23MaintainsOutperformGet Alert
02/22/2022IMGNBuy Now
Immunogen
——$7 → $5MaintainsMarket PerformGet Alert
02/18/2022MRSNBuy Now
Mersana Therapeutics
$2.57522.64%$25 → $16MaintainsOutperformGet Alert
02/17/2022GMABBuy Now
Genmab
$30.2229.05%$42 → $39MaintainsMarket PerformGet Alert
01/20/2022CALABuy Now
Calithera Biosciences
$0.0214900%$20 → $60UpgradeMarket Perform → OutperformGet Alert
01/10/2022KPTIBuy Now
Karyopharm Therapeutics
$1.13607.96%$6 → $8MaintainsMarket PerformGet Alert
12/17/2021BCYCBuy Now
Bicycle Therapeutics
$22.36213.06%—Initiates → OutperformGet Alert
11/11/2021HARPBuy Now
Harpoon Therapeutics
———MaintainsOutperformGet Alert

Recent Analyst Stock Rating News

Where Immunocore Hldgs Stands With Analysts
Now That Crypto Bro Do Kwon Is Out On Bail — Here's A Reminder Of The Fiery Roasting He Received At ETHDenver
Despite the release of Terraform Labs (CRYPTO: LUNA) co-founder Do Kwon and former CFO Han Chong-joon from a Montenegrin jail last week, it is unlikely to alter the negative perception held by many in the crypto community about the pair and their purported
Alibaba To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Wednesday
Barclays boosted Delta Air Lines, Inc. (NYSE: DAL) price target from $38 to $44. Barclays analyst Brandon Oglenski maintained an Overweight rating on the stock. Delta Air shares fell 0.1% to $38.07 in pre-market trading.
Wells Fargo To Surge Around 20%? Here Are 5 Other Price Target Changes For Monday
Goldman Sachs raised Wells Fargo & Company (NYSE: WFC) price target from $46 to $48. Goldman Sachs analyst Richard Ramsden upgraded the stock from Neutral to Buy. Wells Fargo shares rose 1.1% to $40.68 in pre-market trading.
Tesla Hires Former SEC, Justice Department Attorney As Top Lawyer At The Company
Tesla Inc (NASDAQ: TSLA) has hired David Misler, a former Securities and Exchange Commission and U.S.
Putting Robotics To Work In The Warehouse And The Storefront — At Your Doorstep
Robotics companies are exploding onto the market with offerings suited for companies of all sizes. On this episode of At Your Doorstep, Kaylee Nix looks at the way ForwardX Robotics is operating with is robotics-as-a-service model 
Sponsored
June SPAC Merger Vote Calendar: A Look At Upcoming Votes And Stocks To Watch
June just started and the month is already looking busy for SPAC merger votes.
Tesla Ordered By Court To Hand Over Documents Related To Elon Musk's $55B Compensation Plan. Here's Why
Tesla Inc’s (NASDAQ: TSLA) legal team has been asked by a Delaware judge to hand over documents related to the communication before the company board approved a compensation plan in 2018 for CEO Elon Musk, Associated Press
3 Biotech Stocks That Could Double In 12 Months
Biotech stocks are risky investment bets that can swing an investor's fortunes in a big way. An investment decision backed by careful scrutiny and analysis — of a company's pipeline, collaborations, fundamentals, key make-or-break events and cash runway — can fetch disproportionate returns.
Five Prime's Stock Quadruples On Positive Mid-Stage Stomach Cancer Study
Five Prime Therapeutics Inc (NASDAQ: FPRX) shares are seeing astronomical gains Wednesday in reaction to a positive data readout.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free